	US 12,404,503 B2
	Methods and compositions for identifying epitopes
Stephen Elledge, Brookline, MA (US); Tomasz Kula, Brookline, MA (US); and Mohammad Haj Dezfulian, Boston, MA (US)
Assigned to The Brigham and Women's Hospital, Inc., Boston, MA (US)
Filed by The Brigham and Women's Hospital, Inc., Boston, MA (US)
Filed on Oct. 24, 2023, as Appl. No. 18/493,211.
Application 18/493,211 is a division of application No. 16/619,859, granted, now 11,834,653, previously published as PCT/US2018/036663, filed on Jun. 8, 2018.
Claims priority of provisional application 62/516,977, filed on Jun. 8, 2017.
Prior Publication US 2024/0318168 A1, Sep. 26, 2024
Int. Cl. C12N 15/10 (2006.01); A61K 40/11 (2025.01); A61K 40/32 (2025.01); A61K 40/46 (2025.01); C12N 5/0783 (2010.01); C12N 5/09 (2010.01); C40B 20/04 (2006.01); C40B 40/02 (2006.01); G01N 33/50 (2006.01)

CPC C12N 15/1037 (2013.01) [A61K 40/11 (2025.01); A61K 40/32 (2025.01); A61K 40/46 (2025.01); C12N 5/0636 (2013.01); C12N 5/0693 (2013.01); C40B 20/04 (2013.01); C40B 40/02 (2013.01); G01N 33/5047 (2013.01); C12N 2529/10 (2013.01); G01N 2333/96436 (2013.01)]

22 Claims

1. A system for detection of recognized antigen presentation by an antigen presenting cell to a cytotoxic lymphocyte or NK cell comprising:

a) an antigen presenting cell (APC) comprising:

i. an exogenous nucleic acid encoding a candidate antigen, wherein the candidate antigen is expressed and presented with MHC class I and/or MHC class II molecules to a cytotoxic lymphocyte and/or NK cell;

ii. a molecular reporter of Granzyme B (GzB) activity; and

iii. (1) an exogenous nucleic acid encoding inhibitor of caspase-activated deoxyribonuclease (ICAD) in expressible form, (2) an exogenous inhibitory nucleic acid targeting CAD, (3) a CAD knockout, or (4) a caspase knockout; and

b) a cytotoxic lymphocyte and/or NK cell.